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Abstract--The long-term hypoglycemic activity of sulphonylurea drugs has been attributed, in part at 
least, to the stimulation of glucose utilization in extra-pancreatic issues. The novel sulphonylurea, 
glimepiride, gives rise to a longer lasting reduction i  the blood sugar level indogs and rabbits compared 
to glibenclamide (Geisen K, Drug Res 38: 1120-1130, 1988). This cannot be explained adequately by 
elevated plasma insulin levels. This study investigated whether this prolonged hypoglycemic phase was 
based on the drug's abilities to stimulate glucose utilization and affect the underlying regulatory 
mechanisms in insulin-sensitive c lls in vitro. It was found that in the absence of added insulin, 
glimepiride and glibenclamide (1-50/iM) stimulated lipogenesis (3T3 adipocytes) and glycogenesis 
(isolated rat diaphragm) -4.5- and 2.5-fold, respectively, and reduced the isoproterenol-stimulated 
lipolysis (rat adipocytes) up to 40-60%. The increased glucose utilization was correlated with a 3-4- 
fold higher 2-deoxyglucose transport rate and amount of GLUT4 at the plasma membrane, as well as 
with increased activities of key metabolic enzymes (glycerol-3-phosphate cyltransferase, glycogen 
synthase) within the same concentration range. Furthermore, the low K,, cAMP-specific phospho- 
diesterase was activated 1.8-fold, whereas the cytosolic cAMP level and protein kinase A activity 
ratios were significantly owered after incubation of isoproterenol-stimulated rat adipocytes with the 
sulphonylureas. In many of the aspects tudied the novel sulphonylurea, glimepiride, xhibited slightly 
lower EDs0-values than glibenclamide. This study demonstrates correlations existing between drug- 
induced stimulation ofglucose transport/metabolism and cAMP degradation/protein kinase A inhibition 
as well as between the relative efficiencies of,glimepiride and glibenclamide in inducing these extra- 
pancreatic processes. Therefore, it is suggested that the stimulation of glucose utilization by 
sulphonylureas is mediated by a decrease of cAMP-dependent phosphorylation f GLUT4 and glucose 
metabolizing enzymes. The therapeutic relevance of extra-pancreatic effects of sulphonylureas, in 
general, and of the differences between glimepiride and glibenclamide asobserved in vitro in this work, 
in particular, emain to be elucidated. 
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Sulphonylureas are widely used oral drugs for the 
treatment of N IDDMt .  Their initial hypoglycemic 
efficacy is generally explained by acute stimulation 
of the rate of insulin release from the pancreas. 
However, after long-term treatment of N IDDM 
patients with sulphonylurea compounds plasma 
insulin levels often return to pre-treatment levels 
* Corresponding author. Tel. 069-305-4271; FAX 069- 
311454. 
t Abbreviations; cAMP, cyclic AMP; DMEM, 
Dulbecco's minimal essential medium; FCS, foetal calf 
serum; GLUT, glucose transporter isoforms; GPAT, 
glycerol-3-phosphate cyltransferase; IBMX, 3-isobutyl-1- 
methylxanthine; NIDDM, non-insulin-dependent iabetes 
mellitus; PDE, cAMP-specific low K,~ phosphodiesterase; 
PKA, cAMP-dependent protein kinase A; LDM, low 
density microsomes; SDS-PAGE, sodium dodecylsulfate- 
polyacrylamide gel elecrophoresis; TLC, thin layer 
chromatography. 
without concomitant loss of hypoglycemic control or 
improved glucose tolerance [1, 2]. This has been 
attributed to increased glucose disposal by peripheral 
tissues, as observed uring euglycemic clamp studies 
in rats, dogs [3, 4] and NIDDM patients [5, 6]. Direct 
stimulation of basal and/or insulin-dependent glucose 
transport and metabolism in muscle and fat cells 
[7, 8] or, alternatively, an improvement in the overall 
metabolic situation in muscle and fat tissues due to 
increased insulin and reduced glucose levels, 
would explain increased glucose utilization after 
sulphonylurea administration. Experimental con- 
ditions with tightly controlled insulin and glucose 
concentrations will help to discriminate between 
these possibilities. 
Therefore, cellular and cell-free assays were used 
to determine insulin action derived from isolated rat 
and cultured 3T3 adipocytes, as well as isolated rat 
diaphragms. The effects of the sulphonylureas, 
glimepiride and glibenclamide, on the rate of 
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basal and insulin-stimulated glucose transport and 
metabolizing pathways and, in addition, on key 
regulatory processes of glucose metabolism, were 
investigated. The study was designed to allow 
comparison between glimepiride and glibenclamide, 
since it has been shown that glimepiride provokes a
significantly prolonged blood sugar lowering phase 
compared to glibenclamide after oral or i.v. 
application i  dogs and rabbits [9]. These observations 
suggested that glimepiride would exhibit stronger 
direct effects on the two major insulin-sensitive 
peripheral tissues, fat and muscle. The in vitro data 
from this study suggest that the molecular basis 
for the observed multiple stimulatory effects of 
glimepiride and glibenclamide on glucose transport 
and metabolism rely on the interference with the 
cAMP signalling cascade which may, thus, represent 
the primary target for sulphonylureas action in 
peripheral tissues. 
MATERIALS AND METHODS 
Materials. Radiochemicals were bought from 
Amersham-Buchler (Braunschweig, Germany); 3T3 
fibroblast clone A31 was obtained from the American 
Type Culture Collection (CCL 163). Male Wistar 
rats were bred and delivered by the Hoechst 
Aktiengesellschaft (Tierzucht Kastengrund, Ger- 
many); semi-synthetic human insulin (I 81 0182), 
glimepiride (HOE 490) and glibenclamide (Hb 
419) were prepared by the Pharma Synthesis Depart- 
ment of Hoechst Aktiengesellschaft (Frankfurt, 
Germany); stock solutions of glimepiride and 
glibenclamide were prepared on the day of use as 
described previously [10]. 12-[(7-nitrobenz-2-oxa- 
1,3-diazol-4-yl)amino] d decanoic acid was provided 
by Molecular Probes Inc. (Eugene, OR, U.S.A.) 
and dissolved in Krebs-Ringer-phosphate buffer 
containing 1.5% BSA and a 0.5 mM stock solution, 
which was made daily. All the other materials and 
chemicals were obtained as described previously 
[11, 121. 
Cell culture and incubation of 3 T3 adipocytes. This 
was done according to published methods [11] with 
modifications: cells were grown (150 or 35 mm 
culture plates per condition) in DMEM (25 or 2 mL 
per condition) containing 25 mM glucose, 10% FCS 
and antibiotics. Confluent and differentiated cells 
(80-90% of the cells expressed the adipocyte 
phenotype) were washed twice with Krebs-Ringer- 
phosphate buffer and then incubated in the same 
buffer (10 or 1 mL) with sulphonylurea or insulin as 
indicated. 
Metabolic labelling of 3T3 adipocytes. Plates 
(150 mm) were washed twice with methionine-free 
DMEM (HEPES-based) containing 10% FCS, 
5.5 mM glucose, 50 units/mL penicillin, 50/,g/mL 
streptomycin sulphate and then incubated (20 hr, 
37 °) with 10 mL of the same medium supplemented 
with 0.1mM L-[35Slmethionine (0.1mCi) in the 
absence or presence of sulphonylurea nd insulin 
under constant bubbling with 5 % CO2/95% 02. 
The plates were then washed twice with ice-cold 
DMEM containing 10 mM unlabelled methionine. 
Preparation of 3T3 adipocyte homogenate and 
membrane fractions. Prior to homogenization, 
150 mm plates were washed with DMEM as above 
and then once with 10 mL of PBS containing 1mM 
EDTA, 0.25 M sucrose. Monolayers from four plates 
were scraped into 24 mL of ice-cold Tris-HCL/ 
EDTA/sucrose buffer (10mM Tris-HCl, pH 7.4, 
1 mM EDTA, 0.25 M sucrose) and immediately 
homogenized with 10 strokes of a motor-driven 
Teflon-in-glass homogenisator. PMSF (final con- 
centration 0.2 mM) was added to the cell suspension 
prior to homogenization. 
The homogenate was centrifuged (16A)(/0g, 
20 min). The pellet was resuspended in 6 mL of 
10 mM Tris-HCl (pH 7.4), 1 mM EDTA and applied 
on to a sucrose cushion (1.12 M sucrose in Tris-HCl/ 
EDTA). After centrifugation (100,000 g, 1 hr), the 
plasma membranes were removed from the top of 
the sucrose cushion, suspended in 25mL of 
Tris-HC1/EDTA, 0.1 mM PMSF. recovered by 
centrifugation (30,000g, 30min) and resuspended 
in 0.5 mL of Tris-HC1/EDTA, 0.1 mM PMSF. The 
initial 16,000 g supernatant was centrifuged (48,000 g, 
30 min). LDM were recovered from the supernatant 
by centrifugation (200,000g, 2 hr). The pellet was 
suspended in 0.5 mL of Tris-HC1/EDTA, 0.1 mM 
PMSF. The membrane fractions were assayed for 
the activity of the plasma membrane marker enzyme, 
5'-nucleotidase [13], which was enriched 7.5-fold 
(plasma membranes) and 0.4-fold (LDM) towards 
the homogenate. 
Isolation and incubation f rat adipocytes, 
preparation of homogenate and subcellular fractions 
(LDM, cytosol). These were performed according 
to published procedures [12, 14]. 
Preparation and incubation of rat diaphragm and 
preparation of homogenate. Intact hemidiaphragms 
were dissected from male Wistar rats as described [15] 
and incubated in DMEM (10 mL/hemidiaphragm) 
with constant bubbling of O2:CO2 (95:5). For 
treatment with sulphonylureas or insulin, the 
hemidiaphragms were incubated (37 °) in Krebs- 
Henseleit buffer plus 5 mM glucose for the 
periods indicated. For assaying glycogenesis, the 
hemidiaphragms were blotted on tissue, washed 
twice in the same buffer without glucose and 
then incubated with the same buffer (3mL/ 
hemidiaphragm) containing 5raM [U-14C]glucose 
(1/~Ci/mL). The incubation was terminated after 
20 rain by transferring the diaphragms into fresh 
buffer containing 5mM glucose. For preparation of 
the homogenate, the diaphragms were blotted and 
frozen in liquid nitrogen. The frozen diaphragms 
(pool of four) were ground manually in a porcelain 
mortar and then homogenized at 0 ° in 2mL of 
25mM Tris-HCl (pH7.4), 100mM NaF, 5 mM 
EDTA, 0.1 mM PMSF, the homogenate was then 
centrifuged (10,000 g, 20 min). The supernatant was 
used for the determination of radiolabelled glycogen 
for the glycogenesis orglycogen synthase assays (see 
below). 
Glycogenesis. Samples of the supernatant from 
the diaphragm homogenate were heated (45 min, 
100 °) in 30% KOH (1 mL/50 mg tissue) and then 
adjusted to 70% ethanol. After 4 hr at -20 ° the 
samples were centrifuged (2000g, 10min). The 
glycogen pellets were washed four times with 70% 
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ethanol and then assayed for radioactivity by liquid 
scintillation counting. 
Lipogenesis. This was done according to the 
method of Moody et al. [16]. Incorporation of D- 
[3-3H]glucose into toluene-extractable acylglycerides 
was measured after incubation of 3T3 adipocytes 
(35 mm plate per condition) with lmL  Krebs- 
Ringer-phosphate buffer (see below) in the absence 
or presence of sulphonylurea or insulin as indicated. 
Lipogenesis was initiated by the addition of 50/~L 
of 2raM [3H]glucose (0.5/tCi). After incubation 
(90 min, 37 °) the cells were dissolved by addition of 
2 mL toluene-based scintillation cocktail. Following 
30 min of incubation under vigorous shaking and 
transfer of the mixture into scintillation vials, the 
radioactivity was measured in the lipid phase after 
phase separation had been completed (usually 10- 
16 hr). 
Glucose transport. This was measured by the 
uptake of 2-deoxyglucose. 
3T3 adipocytes (according to [17,18] with 
modifications): 35 mm plates were incubated (37 °) 
with 1 mL of Krebs-Ringer-phosphate buffer (140 
mM NaCI, 4.7 mM KCI, 1.25 mM CaCI2, 1.25 mM 
MgSO4, 5 mM sodium phosphate, pH 7.4) in the 
absence or presence of sulphonylurea drug or 
insulin for the periods indicated. Uptake was initiated 
by the addition of 50pL of 2mM 2-[1-3H] - 
deoxyglucose (10 pCi/mL). After 5 min incubation 
in the continuous presence of sulphonylurea and/or 
insulin, uptake was terminated by rapid washing 
with an excess of ice-cold PBS containing 10 mM 
glucose, 0.3 mM phloretin. The monolayers were 
solubilized in 1 mL of 0.2% SDS. The radioactivity 
was measured by liquid scintillation counting. To 
correct for adioactivity non-specifically associated 
with the cells or entrapped in extracellular spaces, 
uptake was determined in parallel in the presence 
of the transport inhibitor cytochalasin B (25/~M). 
These values, which accounted for up to 15% of the 
total radioactivity of the uninhibited plates, were 
subtracted to obtain specific glucose transport. 
Rat diaphragm: Intact washed rat diaphragms 
were incubated (30 min, 37 °) in HEPES-buffered 
saline (25 mM HEPES, 120 mM NaC1, 5 mM KC1, 
1.5 mM CaCI2, 1 mM MgC12, 5 mM glucose, 0.5 mM 
sodium pyruvate, 1.5 mM KHzPO4, pH7.4) under 
constant bubbling with CO2/O2. The diaphragms 
were then washed twice with the same buffer without 
glucose and further incubated (30min) in 5 mL of 
glucose-free buffer in the presence of sulphonylurea 
or insulin. Glucose transport was initiated by addition 
of 50/tL of 10 mM 2-[1-3H]deoxyglucose (10/~Ci/ 
mL) in the absence or presence of25 #M cytochalasin 
B (control). After 15 min, the diaphragms were 
rinsed four times with ice-cold buffer containing 
10 mM glucose and 25 gM cytochalasin B, blotted 
with filter paper and homogenized. Portions of the 
homogenate were used for protein determination. 
One millilitre portions of the supernatant (prepared 
as above) were mixed with 10mL scintillation 
cocktail and counted for radioactivity. Specific 
glucose transport (dpm/mg of protein) was calculated 
as the difference between the diaphragm-associated 
radioactivity measured in the absence (total uptake) 
and presence of cytochalasin B (non-specific uptake). 
Under these experimental conditions transport was 
linear for 30 rain. 
Glycogen synthase. This was assayed as described 
previously [19], with the following modifications. 
After addition of 10 pL of diaphragm homogenate 
(see above) to 200 pL of 25 mM Tris-HC1 (pH 7.4), 
50 mM NaF and 10 mM EDTA (pre-incubated at 
30°), containing either 0.1 or 10raM glucose-6- 
phosphate, the reaction was initiated by sup- 
plementing 0.2 mM [U-14C]UDP-glucose (10 #Ci), 
after 15min the reaction was terminated by the 
addition of 2.5 mL of ice-cold 66% ethanol and 
filtration over pre-wetted Whatman GF/C glass fibre 
discs. The filters were washed, dried and counted 
for radioactivity. Blanks were assayed by adding the 
homogenate to tubes containing the complete 
reaction mixture plus ice-cold ethanol. The fractional 
velocity as the parameter for the portion of glycogen 
synthase active in vivo (I-form) toward the total 
enzyme contents (I- + D-forms) at the time-point of 
homogenization was calculated as the ratio between 
the activities measured at 0.1 (I-form) and 10 mM 
glucose-6-phosphate (I- + D-forms) [20]. 
GPA T. This was assayed as described previously 
[21], with the following modifications. The incubation 
mixture contained 50 mM Tris-HC1 (pH 7.4), 200 mM 
KC1, 1 mM DTY, 150 #M palmitoyl-CoA, 2mg/mL 
BSA, 0.2 mM [3H]glycerol-3-phosphate (2 ~uCi) and 
homogenate from 3T3 adipocytes (see above) in a 
final volume of 0.5 mL. The reaction was started by 
addition of 50/~L of homogenate. After incubation 
(3 min, 37 °) the reaction was stopped with 2 mL of 
water-saturated butanol, followed by 1.5mL of 
butanol-saturated water. The butanol phase was 
separated and washed twice. An aliquot was counted 
for radioactivity. Under these conditions the rate of 
product formation was linear for at least 15 rain. 
The radiolabelled products formed were primarily 
phosphatidic acid (65-70%) and lysophosphatidic 
acid (20-25%), as determined by TLC (not shown). 
PKA. This was assayed according to a published 
method [22], with the following modifications. The 
reaction mixture contained 25/~L of rat adipocyte 
cytosol, 0.4 ~M kemptide, 40 mM Tris-HC1 (pH 7.2), 
2mM DTT, 12.5 mM MgC12, 0.1 mM PMSF, 1 mM 
IBMX, 100/~M [y-32p]ATP (1/~Ci) with or without 
lpM cAMP in a total volume of 100/tL. After 
incubation (10 rain, 30 °) the reaction mixture was 
chilled on ice, then supplemented with 3 mE of 
75 mM phosphoric acid, 100 mM NaF and 10 mM 
ATP, and immediately spotted on phosphocellulose 
filters (Whatman P18). After extensive washing with 
75 mM phosphoric acid, the filters were dried and 
counted for adioactivity. The PKA activity was 
expressed as the ratio between 32p-incorporation 
into kemptide with and without cAMP. This activity 
ratio is a parameter for the portion of PKA active 
in vivo toward total cellular PKA at the time-point 
of homogenization [23]. 
cAMP-specific PDE. This was assayed as described 
previously [24, 25], with the following modifications. 
Up to 50/~L of LDM from rat adipocytes were 
incubated (5 min, 30 °) with 500 nM [2,8-3H]cAMP 
(100 nCi) in 50 mM Tris-HCl (pH 7.4), 0.5 mM DTI',  
5 mM MgC12 and 50 pM PMSF in a total volume of 
0.25mL. The incubation was terminated by the 
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sequential addition of 30/~L of 10 mM IBMX and 
120 ~L of 0.1 N HC1 and heating (5min, 95°). After 
neutralization [120/~L of 0.1 N KOH and 80 #L of 
250mM Tris-HC1/pH7.4], 10~L of crude 5'- 
nucleotidase (5 mg/mL) (Crotalus atrox) was added 
to the mixture, The reaction (30min, 37 °) was 
terminated by the addition of 60~L of 200 mM 
EDTA and 5 mM adenosine. Unreacted cAMP was 
removed by the addition of 1 mL of a 1 : 3 slurry of 
Dowex AG-1X8 (Biorad, Miinchen, Germany). 
Solutions were shaken (5 min, 4 °) and centrifuged 
(1000g, 5 min). Radiolabelled adenosine remaining 
in the supernatant was determined by liquid 
scintillation counting. The assay was proportional 
up to 100 #g of protein and linear for 20 min. 
Determination of cAMP levels. Rat adipocytes 
were homogenized (4 ° ) in the incubation medium 
(0.4 mL 5 × 105 cells/mL) with 0.6 mL of ice-cold 
10% TCA. After 2min on ice and subsequent 
centrifugation (12,000 g, 5 min, 0°), the supernatant 
was extracted with diethyl ether and used for 
determination of the cAMP concentration in 
the organic phase by a radioimmunoassay kit 
(Amersham-Buchler, Braunschweig, Germany). 
Lipolysis. This was assayed as the release of 
glycerol or fluorescent fatty acids from prelabelled 
rat adipocytes. For fluorescent labelling of adipocyte 
lipids, 12mL of adipocyte suspension (2.5 x 105 
cells/mL of HEPES-based Krebs-Ringer buffer 
containing 0.5raM glucose and 0.75% BSA) 
was incubated (90min, 37 °) with 0.3 nM insulin 
and 0.1 mM 12-((7-nitrobenz-2-oxa-l,3-diazol-4- 
yl)amino) dodecanoic acid. Subsequently, the 
adipocytes were washed four times with 50mL 
DMEM containing 5,5 mM glucose, 3% BSA and 
antibiotics by flotation (250 g, 1 min), suspended in 
the same medium at 5% lipocrit, incubated (15 min, 
37 °) with 1 ktM isoproterenol and then supplemented 
with sulphonylurea or insulin. After incubation (4 hr, 
37°), 1 mL aliquots were filtered (Whatman GF/C 
glass fibre filters). Portions of the filtrate (which 
quantitatively contained the released glycerol and 
fatty acids as well as degradation products derived 
thereof) were used for determination of glycerol and 
fluorescent fatty acids, For fatty acid determination, 
500/~L of the filtrate were dried under vacuum, 
dissolved in 50/.tL tetrahydrofurane and 5 ~L aliquots 
were analysed by TLC [silica gel Si60, acetic 
acid : petrol ether: ethanol (3.5 : 1.5:0.5) v/v]. The 
total amount of fluorescent fatty acid and degradation 
products was calculated by fluorometric scanning 
of the TLC plate (total area). For glycerol 
determination, 200/~L of the filtrate were added to 
800/tL water, heated (10min, 70 ° ) and then 
successively made 3% (v/v) perchloric acid and 13% 
(v/v) carbon tetrachloride. The samples were 
mixed and centrifuged (12,000g, 5min). After 
neutralization with KOH the supernatant was 
assayed for glycerol using the spectrophotometric 
method of Wieland [26]. 
Immunoblot analysis of GLUT4. This was 
performed with polyclonal affinity-purified rabbit 
antibodies raised against a synthetic peptide 
corresponding to the COOH-terminal domain of rat 
GLUT4 (residues 495-509) [27]. The plasma 
membrane and LDM fractions were subjected to 
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Fig. l(a). Lipogenesis n 3T3 adipocytes was tested after 
incubation of 35 mm plates with the indicated concentrations 
of glimepiride and glibenclamide for 4 and 20 hr, or insulin 
for 15 min. The 3H-incorporation i to toluene-extractable 
material measured for the basal state (in the absence of 
drug or insulin) and corrected for a blank value (incubation 
mixture lacking cells) was set at 100%. Each point 
represents he mean (+SD; only one-half of the error bars 
are shown due to space limitations) of four different cell 
preparations with four determinations (b)Glycogenesis in 
isolated rat diaphragms was assayed after incubation 
with the indicated concentrations of glimepiride and 
glibenclamide for 4hr or insulin for 30 rain. The ]~C- 
incorporation i to ethanol-precipitated glycogen measured 
for the basal state (in the absence of drug or insulin) was 
set at 100%. Each point represents the mean (-+ SD) 
of six different diaphragm preparations with four 
determinations each. 
SDS-PAGE (25#g protein/lane) and electro- 
phoretically transferred onto nitrocellulose filters 
[28]. Incubations of the filters with primary and 
secondary antibodies (nSI-anti-rabbit IgG from 
goat), autoradiography and quantitative valuation 
of the immunoreactive material by densitometry 
were carried out as described previously [12]. 
lmmunoprecipitation f GLUT4. This was per- 
formed according to published procedures [29] with 
the following modifications: 200/~L of homogenate 
(100¢tg of protein) were centrifuged (150,000g, 
60 rain, 4°), the pellet was dissolved in 50/tL of 
10 mM Tris-HC1 (pH 8.0), 1 mM EDTA, 6 M urea 
and 5% SDS, heated (60 ° , 5min) and again 
centrifuged. The supernatant was supplemented with 
2.5 mL of immunoprecipitation buffer [29] 
containing 1% TX-100 and then with 50 ~L anti- 
GLUT4 antibody which had been adsorbed to 
protein A-Sepharose (50/~L of antiserum was 
incubated with 50 mg protein A-Sepharose beads in 
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Fig. 2(a). 2-Deoxyglucose transport into isolated rat diaphragms was assayed after incubation with the 
indicated concentrations of glimepiride and glibenclamide or 300 nM insulin for 30 min or 4 hr. The 
diaphragm-associated 3H-radioactivity measured for the basal state (in the absence of drug or insulin) 
and corrected for non-specific trapping (in the presence of 25 ~M cytochalasin B) was set at 100%. 
Each point represents the mean (-+ SD) of four different diaphragm preparations with four determinations 
each, (b)-(d) 2-Deoxyglucose transport into 3T3 adipocytes was assayed after incubation of 35 mm 
plates for various periods (panel b) or 20 hr (panels c and d) with 20/~M glimepiride and glibenclamide 
(panels b and d) or the indicated rug concentrations r 30 nM insulin (panel c) prior to further 
incubation in the absence (panels b and c) or presence of various concentrations of insulin (panel d) 
for 15 min. The cell-associated 3H-radioactivity measured for the basal state (in the absence of drug or 
insulin) and corrected for non-specific trapping (in the presence of 25 #M cytochalasin B) was set at 
100%. Each point represents the mean (-+ SD) of five different cell preparations with four determinations 
each. 
(d) 
450/~L immunoprecipitation buffer for 2hr at 
4 ° under head-over rotation. The beads were 
centrifuged, washed twice with buffer and finally 
suspended in 0.5 mL of buffer). After incubation 
(10hr, 4 °, head-over rotation), the immuno- 
precipitates were collected by centrifugation 
(12,000 g, 30 sec), washed sequentially with 2 mL of 
immunoprecipitation buffer containing 0.5 and 0.1% 
TX-100 and finally dissolved in 50 ~tL of 10 mM Tris- 
HCI (pH 8.0), 1 mM EDTA,  6 M urea and 2% SDS. 
The supernatant of a centrifugation was analysed by 
SDS-PAGE and fluorography. The relative amount 
of immunoprecipitated GLUT4 was calculated from 
spectrophotometric analysis of the silver grains 
eluted from the darkened areas (bands) of the film 
[301. 
Miscellaneous procedures. Published procedures 
were used for SDS-PAGE (14% separating el) in 
the presence of 6M urea, fluorography [31] and 
protein determination with the amidoblack staining 
method [32]. 
RESULTS 
Stimulation of glucose utilization (lipogenesis and 
glycogenesis) 
Long-term incubation of 3T3 adipocytes with 
glimepiride and glibenclamide concentration-depen- 
dently stimulated lipogenesis up to 4-fold (cor- 
responding to 35-40% of the maximal insulin- 
induced lipogenesis as observed with 30 nM insulin 
after 15 min incubation) (Fig. la). This effect was 
clearly more pronounced after 20 hr compared to 
4 hr incubation. The EDs0-values for glimepiride and 
glibenclamide were comparable (1.7 vs 2.9 pM) and 
independent of the incubation time. 
Incubation for 4 hr of isolated rat hemidiaphragms 
with glimepiride and glibenclamide concentration- 
dependently stimulated glycogenesis up to 2.5-fold 
(corresponding to 65% of the maximal insulin effect 
as observed with 100nM insulin after 30min 
incubation) (Fig. lb), with EDs0-values of 0.4/~M 
(glimepiride) and 0.8 juM (glibenclamide). Thus, the 
overall glucose-utilizing pathways of lipid and 
glycogen synthesis are stimulated by both drugs, 
with glimepiride being slightly more effective than 
glibenclamide. 
Stimulation of glucose transport 
Under physiological p asma glucose levels glucose 
transport isthought o be rate-limiting for lipogenesis 
and glycogenesis [33]. Therefore, it was wondered 
whether glimepiride and glibenclamide stimulated 
transport of the non-metabolizable sugar analogue, 
2-deoxyglucose, in 3T3 adipocytes and isolated rat 
diaphragms. Incubation of the diaphragms for 30 rain 
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Fig. 3(a) and (b). Total amount of GLUT4 protein in 3T3 
adipocytes was assayed after incubation of 150 mm plates 
with the indicated concentrations of glimepiride and 
glibenclamide (panel a) or 20 klM drug (panel b) for 20 hr 
(panel a) or the indicated periods (panel b). The 
immunoreactive GLUT4 in total cellular membranes 
measured for the basal state (in the absence of drug or 
insulin) was set at 100%. Each value represents he mean 
(+-SD) of three different cell preparations with four 
determinations each. (c) The amount of newly synthesized 
GLUT4 protein in 3T3 adipocytes (metabolically abelled 
with [35S]methionine) was assayed after incubation of 
150mm plates with the indicated concentrations of 
glimepiride and glibenclamide, for 20hr. The immu- 
noprecipitated radiolabelled GLUT4 in total cellular 
membranes in the basal state (in the absence of drug or 
insulin) was set at 100%. Each point represents he mean 
(+SD) of three cell preparations with two determinations 
each, 
with glimepiride and glibenclamide concentration- 
dependently increased glucose transport up to 1.7- 
fold with EDs0-values of 3.2 yM for both drugs (Fig. 
2a). Drug exposure for 4 hr caused a left-ward shift 
of the dose-response curves (EDs0-value = 0.7/tM 
for glimepiride, 1.2 ktM for glibenclamide) with no 
increase in the maximal response. In contrast, 
maximal glimepiride and glibenclamide stimulation 
of 2-deoxyglucose transport in 3T3 adipocytes 
required 24hr drug exposure (Fig. 2b). Under 
these conditions glimepiride and glibenclamide 
concentration-dependently stimulated glucose trans- 
port up to 7- and 6-fold with EDs0-values of 3.2 and 
5.2/tM, respectively (corresponding to 25-30% 
of the maximal insulin stimulation) (Fig. 2c). 
Submaximal insulin concentrations (0.05-1 nM) plus 
glimepiride or glibenclamide (20 #M) stimulated 2- 
deoxyglucose transport in an additive fashion, which, 
however, did not exceed the maximal insulin effect 
(Fig. 2d). The EDs0-value for glucose transport 
stimulation by insulin (1.2 riM) was reduced in the 
presence of glimepiride (0.5 nM) and glibenclamide 
(0.8nM). Thus, in 3T3 adipocytes, both sul- 
phonylureas directly activated glucose transport 
independently of insulin, and potentiated insulin- 
stimulated glucose transport, albeit to a moderate 
degree. Stimulation of glucose transport may be 
based on increased de novo synthesis of GLUT 
protein and/or recruitment of GLUT from intra- 
cellular stores (LDM) to the cell surface (termed as 
translocation [34, 35]). To study these possibilities, 
the amount of GLUT4, the major insulin-regulatable 
GLUT isoform in 3T3 adipocytes (for a review see 
Ref. [36]), was determined in total cellular 
membranes or, after subcellular fractionation, in the 
LDM and plasma membranes by immunoblotting 
with anti-GLUT4 antibodies. Incubation (20 hr) of 
3T3 adipocytes with glimepiride and glibenclamide 
concentration-dependently increased the total 
amount of GLUT4 up to 2-fold (with 20 ~M drug) 
(Fig. 3a). Long-term incubation (>4 hr) was required 
for a significant drug-induced increase, suggesting 
stimulation of GLUT4 synthesis (Fig. 3b). This was 
confirmed by immunoprecipitation with anti-GLUT4 
antibodies of total membrane proteins from 3T3 
adipocytes which had been metabolically labelled 
with [35S]methionine for 20 hr in the presence of 
glimepiride or glibenclamide (Fig. 3c). Glimepiride 
and glibenclamide concentration-dependently 
increased the amount of total immunoprecipitated 
radiolabelled GLUT4 1.7- and 1.6-fold (at 50 uM), 
respectively, with EDsirvalues (1.2 vs 2.3~tM) 
comparable to those observed for total immu- 
noreactive GLUT4 (0.8 vs 1.5 I~M). 
In addition, both drugs stimulated translocation 
of GLUT4 as revealed by immunoblotting of LDM 
and plasma membranes with anti-GLUT4 antibodies 
(Table l). Incubation (20 hr) with glimepiride and 
glibenclamide caused a concentration-dependent 
translocation of GLUT4 approaching 4(/-50% of the 
maximal insulin response, corresponding to a 3.5- 
fold increase of plasma membrane GLUT4. 
Stimulation of  glucose metabolizing enzvmes. 
In addition to drug-stimulated glucose transport 
and metabolism, the latter, at least in part, being 
due to increased substrate availability, glucose 
metabolizing enzymes may be activated in response 
to glimepiride and glibenclamide independently of
the mass effect. Therefore, the key regulatory 
enzymes of lipogenesis and glycogenesis, GPAT and 
glycogen synthase, were investigated. 
The esterification of glycerol-3-phosphate o 
Extra-pancreatic effects of sulphonylurea drugs 
Table 1. Effects of sulphonylureas on the translocation of
GLUT4 in 3T3 adipocytes 
Total immunoreactive GLUT4 
Incubation in the plasma membrane (%) 
Basal 8.3 -+ 2.7 
Insulin 44.2 +- 9.5 
Sulphonylurea (#M) Glimepiride Glibenclamide 
0.5 8.1 -+ 3.5 6.8 +- 2.7 
1 10.8 +- 2.6 9.6 -+ 4.0 
5 12.9 -+ 3.9 15.9 -+ 4.6 
10 16.7 -+ 4.4 20.3 -+ 4.9 
20 19.8 + 5.3 23.6 -+ 4.1 
50 22.2 + 4.8 23.1 -+ 5.2 
Translocation of GLUT4 in 3T3 adipocytes was assayed 
after incubation of 150mm plates with the indicated 
concentrations of glimepiride and glibenclamide for 20 hr 
or insulin (5 nM) for 30 rain. 
The amount of immunoreactive GLUT4 identified by 
immunoblotting in the plasma membranes was calculated 
as the percentage of the total amount of GLUT4 recovered 
in cellular membranes after incubation with drug or insulin 
which was set at 100% for each concentration. Each value 
represents he mean (-+ SD) of four adipocyte preparations 
and fractionations with three determinations each. 
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Fig. 4. GPAT activity in the homogenate from isolated rat 
adipocytes was assayed after incubation of 20 mL of 
adipocyte suspension (5 x 105 cells/mL) with the indicated 
concentrations of glimepiride and glibenclamide for 4 and 
20hr, or with 30nM insulin for 30min. The 3H-  
incorporation i to butanol-extractable material measured 
for the basal state (in the absence of drug or insulin) and 
corrected for a blank value (incubation mixture lacking 
homogenate protein) was set at 100%. Each point 
represents the mean (-+ SD) of five different cell and 
homogenate preparations with four determinations each. 
neutral lipids, phospholipids and (lyso)phosphatidic 
acid by GPAT was stimulated up to 2-fold with EDs0- 
values of 1.9 and 3.7/~M, respectively, when 
assayed with homogenate from glimepiride- and 
glibenclamide-treated 3T3 adipocytes (Fig. 4). The 
concentration-dependent stimulation was more 
pronounced after 20 hr than 4 hr incubation. 
After 4 hr exposure of isolated rat diaphragms to 
glimepiride and glibenclamide the fractional velocity 
for glycogen synthase concentration-dependently 
increased up to 6-fold (at 20/~M) (Fig. 5a). 
Glimepiride was more effective than glibenclamide 
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Fig. 5. Glycogen synthase activity ratio in the homogenate 
of isolated rat diaphragm was assayed after 4 hr incubation 
with the indicated concentrations of glimepiride and 
glibenclamide or300 nM insulin. Each point represents he 
mean (_+ SD) of the fractional velocity (see Materials and 
Methods) of three different diaphragm preparations with 
four determinations each. 
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Fig. 6. PKA activity ratio in the cytosol of isolated rat 
adipocytes was assayed after incubation of 40mL 
of adipocyte suspension (5 x 105 cell/mL) with 1 ~tM 
isoproterenol for 15 min and then with the indicated 
concentrations of glimepiride and glibenclamide or 5 nM 
insulin for 4 hr. Each point represents the mean (-+ SD) 
of the activity ratio (see Materials and Methods) of three 
different adipocyte preparations with three determinations 
each. 
(EDs0-value 0.8 vs 2.0#M). Gel filtration over 
Sephadex G-25 of homogenates prepared f om drug- 
treated diaphragms did not inhibit the activation of 
glycogen synthase (data not shown), suggesting that 
the activation was not due to elevated levels of 
glucose-6-phosphate as a consequence of increased 
glucose transport. Total glycogen synthase activity 
(I- and D-forms) as measured in the presence of 
10 mM glucose-6-phosphate was not altered. Both 
drugs (at 10 #M) and low concentrations of insulin 
(up to 10 nM) stimulated the fractional velocity in 
an additive fashion (data not shown), approaching 
120% of the maximal insulin effect. The EDs0-value 
for insulin stimulation (35 nM) was reduced in the 
presence of glimepiride (16 nM) or glibenclamide 
(23nM). Elevated basal and insulin-stimulated 
fractional velocities were not observed if the 
homogenate was prepared 15 min after drug addition. 
Effects on the cAMP regulatory cascade 
GPAT and glycogen synthase, which are both 
stimulated by glimepiride and glibenclamide in 3T3 
adipocytes and the rat diaphragm, are regulated 
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Table 2. Effects of sulphonylureas on the isoproterenol- 
stimulated lipolysis in rat adipocytes 
Total glycerol release 
Incubation (%) 
Insulin 30.6 + 8.9 
Sulphonylurea (#M) Glimepiride Glibenclamide 
0,5 92.8 -+ 15.8 95.2 -+ 12.4 
l 76.4 -+ 18.9 82.0 -+ 19.3 
2 70.8 -+ 14.5 68.4 -+ 12.5 
5 63.6 -+ 11.6 58.7 + 10.4 
10 60.1 _+ 14.2 48.8 -+ 16.7 
20 56.5 -+ 8.9 44.8 -+ 12.0 
50 53.1 -+ 12.7 42.7 -+ 9.7 
Fluorescent fatty acid release 
(%1 
Insulin 36.7 -+ 10.3 
Sulphonylurea (#M) Glimepiride Glibenclamide 
0.5 91.7 -+ 24.9 95.7 -+ 17.8 
1 76.3 -+ 19.4 86.4 -+ 28.1 
2 72.3 -+ 14.1 73.7 -+ 18.5 
5 67.3 -+ 20.5 69.6 -+ 16.4 
10 63.1 + 13.1 64.7 -+ 18.6 
20 58.3 + 19.4 59.7 + 12.1 
50 56.3 + 10.5 55.3 -+ 13.6 
lsoproterenol-stimulated lipolysis was as ayed as glycerol 
and fatty acid release from rat adipocytes (pre-labelled 
with fluorescent fatty acids) after incubation of 50 mL of 
adipocyte suspension (5 ×105 cells/mL) in the presence of 
1/~M isoproterenol for 15 rain and subsequently with the 
indicated concentrations of glimepiride and glibenclamide 
or 5 nM insulin for 4 hr. 
The amount of glycerol and fluorescent fatty acid (and 
degradation products) recovered in the cell-free filtrate 
from isoproterenol-treated adipocytes which had not been 
incubated with drug or insulin was set at 100%. Each value 
represents the mean (-+ SD) of three different adipocyte 
preparations with four determinations each. 
by cAMP-dependent phosphorylation leading to 
inactivation. Therefore, the effect of the two 
sulphonylureas onthe cAMP metabolism and on the 
activity of PKA in isolated rat adipocytes, which had 
been challenged for fl-adrenergic response by pre- 
incubation with isoproterenol, were studied. The 
PKA activity ratio was high after isoproterenol 
stimulation of rat adipocytes and was reduced by 
subsequent sulphonylurea treatment (4 hr, Fig. 6). 
The concentration-dependent inhibition of PKA 
approached up to 40% of the maximal insulin effect 
and was slightly more pronounced for glimepiride 
than glibenclamide (ICs0 = 0.66 vs 1.3 pM). 
To corroborate the inhibitory effect of glimepiride 
and glibenclamide on PKA activity, it was then 
studied whether the low PKA activity ratio was 
correlated with diminished lipolysis. Glimepiride 
and glibenclamide antagonized the isoproterenol- 
stimulated lipolysis in isolated rat dipocytes (Table 
2). The parallel concentration-dependent inhibition 
of glycerol and fatty acid release was first observed 
30 rain after drug addition (data not shown) and 
reached a maximum after 4 hr with 50/~M drug 
(corresponding to the half-maximal insulin effect). 
The PKA activity ratio is assumed to reflect mainly 
the intracellular cAMP concentration at the time- 
point of homogenization [23]. Consequently, it was 
studied whether glimepiride and glibenclamide 
caused a reduction in the high cytosolic AMP level 
in isoproterenol-stimulated adipocytes. Care was 
taken to minimize degradation of cytosolic cAMP 
after homogenization of the isoproterenol- and, 
subsequently, drug-treated cells (see Materials and 
Methods). Both drugs provoked a concentration- 
dependent decline of cAMP levels up to 50% of the 
isoproterenol-induced concentration (Table 3). 
Finally, it was studied whether sulphonylureas 
reduced cytosolic cAMP by promoting its degra- 
dation. In fact, the activity of the particulate low K m 
cAMP-specific PDE in LDM from rat adipocytes 
which had been incubated with glimepiride and 
glibenclamide for 2hr concentration-dependently 
increased up to 2-fold (at 20~tM) compared to 
untreated control cells (Fig. 7), with EDs0-values of 
0.9 and 2.0/~M, respectively. 
DISCUSSION 
A large number of studies during the past three 
decades have demonstrated multiple effects of 
sulphonylurea drugs on isolated normal and insulin- 
resistant rat [12, 37-43] and mouse 3T3 adipocytes 
[44-46], cultured myocytes [47-51], isolated rat 
diaphragms [52] and perfused rat hind limbs [53] 
(for a review see Ref. [54]). Among them are the 
stimulation of glucose transport [12, 37, 38, 41, 44- 
53], lipogenesis [40] and glycogenesis [43], as well 
as the inhibition of lipolysis [39]. The multiple ffects 
of sulphonylureas on glucose utilization in vitro 
suggest the induction of one or several basic 
molecular mechanism(s) which is(are) responsible 
for the regulation of key metabolic pathways. 
As described in this study, the maximal 7-fold 
stimulated glucose transport in 3T3 adipocytes after 
20 hr incubation with glimepiride and glibenclamide 
is explained in part by the 4-fold amount of plasma 
membrane GLUT4. This may be based on both 
activated synthesis and translocation of GLUT4. 
Stimulation of GLUT gene expression and trans- 
location by tolbutamide and glibenclamide has been 
described previously for adipose [41, 42, 44] and 
muscle cells [48, 50]. Since glimepiride and insulin 
stimulations are additive only, glimepiride may 
regulate GLUT4 translocation by bypassing the 
insulin signal transduction cascade. Elevated levels 
of phosphorylated GLUT4 in isolated rat adipocytes 
incubated with glucose, insulin and glutamine in 
primary culture [12], or in rat adipocytes isolated 
from Streptozotocin-diabetic rats [55], have been 
correlated with diminished glucose transport activity 
[56]. There is some evidence for Ser/Thr-phos- 
phorylation of GLUT4 by PKA during induction of 
insulin resistance [57-59]. Treatment of insulin- 
resistant cultured adipocytes with glimepiride r duces 
the GLUT4 phosphorylation state to a significantly 
higher degree than insulin [12], possibly by 
interference with PKA activity. This would explain 
the drug's ability to induce GLUT4 translocation i
insulin-resistant adipocytes if only the dephos- 
Extra-pancreatic effects of sulphonylurea drugs 
Table 3. Effects of sulphonylureas on the cAMP-level in rat adipocytes 
Incubation cAMP [pmol/106 adipocytes] 
Basal 26.3 -+ 6.5 
Isoproterenol 175.6 -+ 23.7 
Isoproterenol + insulin 52.5 -+ 13.6 
Isoproterenol + sulphonylurea ( /~M)  Gl imep i r ide  Glibenclamide 
0.5 168.7 -+ 44.3 173.4 -+ 34.6 
1 161.0 -+ 29.6 164.5 -+ 38.9 
2 148.8 +- 21.3 154.1 -+ 40.6 
5 127.8 -+ 23.4 138.2 -+ 25.6 
10 113.8 -+ 27.6 120.8 -+ 18.9 
20 103.3 -+ 31.6 112.2 +- 26.7 
50 110.4 +- 20.5 124.5 -+ 29.8 
100 122.5 -+ 23.1 129.5 -+ 22.4 
cAMP levels in the cytosol fisolated rat adipocytes were assayed after incubation 
of 20 mL of adipocyte suspension (5 × 105 cells/mL) in the absence (basal) or 
presence of 1 ttM isoproterenol for 15 min and subsequently with the indicated 
concentrations of glimepiride and glibenclamide or 5 nM insulin for 4 hr. Each value 
represents the mean (-+ SD) of four different adipocyte preparations with four 
determinations each. 
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Fig. 7. cAMP-specific PDE activity in LDM from isolated 
rat adipocytes was assayed after 2 hr incubation of 40 mL 
of adipocyte suspension (5 × 105 cells/mL) with the 
indicated drug concentrations or 5 nM insulin. Each point 
represents the mean (-+ SD) of five different adipocyte 
preparations with two determinations each. 
phorylated GLUT4 is competent for translocation 
and residence at the plasma membrane. 
Glimepiride and glibenclamide l ad to activation 
of GPAT and glycogen synthase presumably through 
impairment of cAMP-dependent phosphorylation f 
the enzymes. This is also the mechanism for their 
stimulation by insulin [60, 61], and would parallel 
the postulated molecular mechanism for the 
glimepiride stimulation of GLUT4 translocation. In
support of this hypothesis the fact that glimepiride 
and glibenclamide reduce th portion of active PKA 
within the same concentration range effective in 
stimulating glucose transport. A moderate inhibition 
of PKA has been described previously for tolbutamide 
[62]. The diminished PKA activity is due mainly to 
significantly owered levels of cytosolic cAMP after 
glimepiride- and glibenclamide-treatment of rat 
adipocytes. However, a direct inhibition of the 
catalytic subunit of PKA, cannot be excluded, as it 
has been demonstrated for PKA from rat liver 
[63, 64]. In parallel with reduced cytosolic cAMP 
levels, the drugs stimulate the activity of the 
microsomal low Km cAMP-specific PDE in rat 
adipocytes within the same concentration range. 
This corroborates previous reports concerning 
sulphonylurea action on PDE activity [65, 66]. At 
present it is not known whether a sulphonylurea- 
induced inhibition of adenylate cyclase, as reported 
for rat heart and liver [67], supports the decline of 
cAMP levels. The inhibitory effects of glimepiride 
and glibenclamide on cAMP level and PKA activity 
are confirmed by the antagonism of isoproterenol- 
stimulated lipolysis in drug-treated rat adipocytes. 
Significantly less pronounced antilipolytic activity 
has been demonstrated for tolbutamide [39]. 
That treatment of3T3 adipocytes with glimepiride 
stimulates a glycosyl-phosphatidylinositol-specific 
phospholipase C [10] may be of relevance for a 
unifying molecular basis for the inhibition of PKA 
and stimulation of PDE by sulfonylureas. The 
degradation products of glycosyl-phosphatidyl- 
inositol ipids and/or glycosyl-phosphatidylinositol- 
anchored membrane proteins, phosphoinositol- 
glycans and phosphoinositolglycan-peptides, have 
been documented to inhibit PKA [68, 69] and to 
stimulate PDE [70, 71] if assayed in cell-free systems 
derived from adipocytes or hepatocytes which have 
been pre-incubated with these structures. 
The physiological meaning of the stimulation of 
glucose utilization and inhibition of lipolysis by 
sulphonylureas observed in vitro is still a matter of 
intense debate (for two opposing views see Refs. 
[54,72]). The EDs0-values of glimepiride and 
glibenclamide in these in vitro assays were two to 
three orders of magnitude higher than the 
concentration of free not protein-bound drug, as 
usually measured in the serum of NIDDM 
patients (1-10 nM). However, local accumulation of 
sulphonylureas in muscle and fat tissues cannot be 
excluded. Extra-pancreatic effects have been thought 
to be responsible for the hypoglycemic action of 
sulphonylureas following the acute phase of insulin 
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release [73-75; for a review see Ref. 76]. In rabbits 
and dogs the blood sugar lowering phase after the 
initial period of insulin release is significantly longer 
for glimepiride than for glibenclamide [9]. To support 
extra-pancreatic effects this difference should be 
reflected in the effects of the two drugs on glucose 
utilization and its underlying regulatory mechanisms 
in vitro. The present study reveals that, at this 
level, glimepiride and glibenclamide xhibit similar 
effective concentration ranges and maximal 
responses. However,  the data obtained from many 
assays of glimepiride and glibenclamide resulted in 
slightly lower calculated EDs0- and IC'50-values, 
respectively. This is reflected in subtle left-ward 
shifts of the dose-response curves for glimepiride. 
The differences obtained with these experimental 
designs were only at the threshold of significance. 
Nevertheless, they were obtained with a considerable 
number of independent assays carried out with 
different cell types. Taken together, the present 
study strengthens the view that: (1) the multiple 
effects of sulphonylureas on fat and muscle cells in 
vitro are based on a common molecular mechanism, 
i.e. the inhibition of cAMP-dependent phos- 
phorylation, which is used by glimepiride slightly 
more efficiently than by glibenclamide; (2) the 
prolonged hypoglycemic action of sulphonylureas in
the absence of correspondingly elevated plasma 
insulin levels in vivo, which is more pronounced 
with glimepiride than glibenclamide, is correlated 
with their efficacy in stimulating lucose utilization 
and the underlying regulatory steps in muscle and 
fat tissues. 
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